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Background: Zingiber officinale (ZO, family Zingiberaceae) has been reported for its antiemetic activity against
cancer chemotherapy induced emesis in animal models and in clinics. Current study was designed to investigate
ZO for potential usefulness against cisplatin induced vomiting in pigeon and its effects on central and peripheral
neurotransmitters involved in the act of vomiting.
Methods: Zingiber officinale acetone fraction (ZO-ActFr) was investigated for attenuation of emesis induced by
cisplatin in healthy pigeons. Neurotransmitters DA, 5HT and their metabolites DOPAC, HVA and 5HIAA were
analyzed using High Performance Liquid Chromatography system coupled with electrochemical detector in area
postrema, brain stem and intestine. Antiemetic effect of ZO-ActFr was correlated with central and intestinal
neurotransmitters levels in pigeon.
Results: Cisplatin (7 mg/kg i.v.) induced emesis without lethality upto the observation period. ZO-ActFr (25, 50 &
100 mg/kg) attenuated cisplatin induced emesis ~ 44.18%, 58.13% (P < 0.05) and 27.9%, respectively; the reference
drug, metoclopramide (MCP; 30 mg/kg), produced ~ 48.83% reduction (P < 0.05). ZO-ActFr reduced (P < 0.05 - 0.001)
5-hydroxytryptamine (5HT) concentration in the area postrema, brain stem and intestine at 3rd hour of cisplatin
administration, while at the 18th hour ZO treatments attenuated the dopamine upsurge (P < 0.001) caused by cisplatin
in the area postrema and 5HT concentration (P < 0.01 - 0.001) in the brain stem and intestine. ZO treatments alone did
not altered the basal neurotransmitters and their metabolites in the brain areas and intestine.
Conclusion: The behavioral study verify the antiemetic profile of ZO against cisplatin induced emesis in the pigeon,
where central and peripheral neural evidences advocate the involvement of serotonergic mechanism at initial time
point (3rd hr), while the later time point (18th hr) is associated with serotonergic and dopaminergic component in the
mediation of its antiemetic effect.
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Cytotoxic agents like cisplatin and cyclophosphamide
are having the side effects of nausea and vomiting most
feared by patients undergoing cancer chemotherapy [1].
The D2 receptor blocker “metoclopramide” was found to
be effective against Chemotherapy Induced Vomiting
(CIV) at higher doses, where the anti-emetic effect is
reported to be mediated through antagonism of 5-hydroxy* Correspondence: Ihsanmkd@gmail.com
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unless otherwise stated.tryptamine type 3 (5HT3) receptors [2,3]. These findings
of 5HT3 mediated anti-emetic effect of metoclopramide
led to the discovery of 5HT3 receptor antagonists.
The failure of single anti-emetic agent for the control
of CIV is steering the etiology to be multifactorial, and
there are evidences for the involvement of many neuro-
transmitter systems including serotonergic [4,5], dopa-
minergic [6,7] and neurokininergic [8,9] systems acting
in emetic circuitry at different time pointes. In the past
decades, major advances have been made in the under-
standing of the neuro-pharmacology of the emetic
pathways.his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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mary culprit in the initiation of vomiting response espe-
cially considering CIV [10]. Upto 95% of 5HT is present
in the enterochromaffin (EC) cells in the gastrointestinal
mucosa along with substance P [11,12], which is released
by the noxious stimulus caused by Highly Emetogenic
Chemotherapy (HEC) agents like cyclophosphamide and
cisplatin [5,13]. Furthermore, in human and animal studies,
there are evidences for the increased level of 5-Hydroxy
Indole Acetic Acid (5HIAA, urine) [14,15], 5HT in the in-
testinal mucosa (ileal segment), Tryptophan Hydroxylase
(TPH, ileum), Aromatic L-amino Decarboxylase (AADC,
ileum) [16] and in the brain stem following cisplatin treat-
ment, while a decrease in Monoamine Oxidase (MAO,
ileum) has also been reported [16]. This enhancement in
5HT biosynthesis and reduction in degradation ultimately
lead to the upsurge of serotonin which is imperative in the
mediation of vomiting act.
Dopamine (DA) is also among the several neurotrans-
mitters, which theater its role in the genesis of vomiting,
through selective activation of D2 receptors, localized in
the limbic system, hypothalamus, amygdala and in the
brain stem emetic circuitry [17,18]. Dopaminergic ago-
nists like morphine and apomorphine has been reported
to be emetic in a variety of species including dogs [19],
ferrets [6,20] and human [21]. The emetic action of
apomorphine and loperamide has been suggested to be
mediated in the chemoreceptor trigger zone/area post-
rema through stimulation of dopamine receptors, as abla-
tion of this area abolished the vomiting response [17,22].
Plants are proving themselves as important therapeutic
entities that are economical, safe and readily available
particularly in rural communities [23-26]. Zingiber offici-
nale (Ginger) has been used as a natural herb in the
treatment of vomiting for more than 2000 years in
China and as common spice for cooking in Asian coun-
tries [27]. One of its therapeutic indications has always
been in the treatment of nausea and vomiting, as its
carminative, spasmolytic and aromatic properties suggest
its direct effects on the gastrointestinal system. The
major components present in ginger extract which is a
mixture of homologues having 10, 20 and 14 carbon
atoms in side chain that are designated as gingerols [28].
Gingerols, in particular 6-gingerol has been identified as
the major active constituent responsible for its charac-
teristic taste and is reported to enhance gastrointestinal
motility and have capability to antagonize 5HT3 recep-
tors in the gastrointestinal tract (GIT) [29], which sup-
ports its anti-emetic property.
Keeping in view the gastroprokinetic and 5HT3 receptor
antagonist property, the present study was designed to
screen the intrinsic anti-emetic activity of Zingiber offi-
cinale (ZO) against cisplatin induced emesis in pigeon.
Furthermore, considering the relevance of serotoninand dopamine in emesis, this study was extended to
evaluate the participation of these monoamine neuro-
transmitters and their metabolites in cisplatin induced
vomiting, and to examine the impact of Zingiber offici-
nale (ZO) on serotonin, dopamine and their metabolites
centrally in specific brain areas involved in the act of
vomiting and peripherally in the intestine in pigeon.
Methods
Animals
Pigeons of either sex (mixed breed, Department of
Pharmacy, University of Peshawar, Pakistan) weighing
between 250 - 350 g were used. They were housed in
groups of eight at 22–26°C under a 12 h light/dark
cycle and had free access to food (locally available food;
Millet +Wheat) and water before and during expe-
rimentation. All the experimental procedures were
approved by the Ethical Committee of the Department
of Pharmacy, University of Peshawar (Ref. No 5/EC/
Pharm; Dated: June 15, 2011) and are in accordance
with the UK Animal Scientific Procedure Act, 1986.
Drugs and chemicals
High Performance Liquid Chromatography (HPLC) grade
acetonitrile, methanol, 1-octane sulphonic acid sodium
salt (Fisher scientific U.K.), sodium dihydrogen orthophos-
phate and ethylene diamine tetra acetic acid (EDTA) were
purchased from the Merck local distributor in Peshawar,
Pakistan. Noradrenaline, DOPAC, Dopamine, 5HIAA,
HVA, serotonin were from Acros organics, Belgium.
Cisplatin was from Korea United Pharm. Inc. (Korea)
and was dissolved in normal saline at 65 - 70°C. Meto-
clopramide (MCP) was purchased in solution from
GlaxoSmithKline (GSK Pakistan Ltd.). Acetone was
from Haq Chemicals Peshawar (Pakistan). The plant
rhizome were purchased from a local market at Mardan
and was authenticated by Prof. Dr. Muhammad Ibrar,
Department of botany, University of Peshawar.
Extraction of Zingiber officinale
A total of 0.5 kg of fresh ginger was bought from the
central vegetable market in Mardan, Pakistan. A sample
was deposited at the Herbarium of the Department of
Botany, The University of Peshawar, Peshawar, with the
voucher number (voucher No 20017 - pup). Ginger was
washed for any contaminants and then sliced to expose
the inner part. It was then soaked in 2 L of acetone and
kept for a total of 3 days, thrice. The combined filtrate
was concentrated in a rotary evaporator to obtain a thick
extract with a yield of 4.72% (Figure 1).
Drug formulation
Cisplatin was dissolved in normal saline by heating up to
60°C, cooled upto 40 - 45°C and immediately administered.
Zingiber officinale (coarsely sliced rhizomes)
0.5 kg, acetone, X3
MarcEvaporated
Extract
Residue (yield 23.6 grams)
Figure 1 Extraction scheme for Zingiber officinale acetone fraction.
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in normal saline by gentle agitation and sonicated to get
clear solution and administered.
Drug administration
Intravenous and intramuscular routes were used for
drug administration via brachial wing vein and chest
muscle, respectively. Immediately, after the last injection,
the animals were put back in the specially designed
confining/observation cages and the number of emesis
episodes and latency to first vomit were recorded for
24 h. ZO-ActFr and MCP or respective vehicles, were
administered 30 minutes before cisplatin administration.
At the end of experiment, body weight loss was calcu-
lated. Subsequently, the animals were decapitated to
terminate the experiment.
Anti-emetic assay
On the day of experiment, the pigeons were placed in
individual cages specially designed for video observation.
After cisplatin (7 mg/kg) [30] administration at t = 0 [31]
the behavior of the pigeon was recorded for 24 h. Food
and water were available during the observation period
and each animal was used only once. The response with
or without oral expulsion was considered as one vomit-
ing episode [32]. A vomiting episode was considered
completed when the pigeon adapted relaxed posture.
Tissue sampling for neurotransmitters analysis
At the end of each experiment, animals were decapitated
and the brain areas and intestinal samples 5 – 6 cm
from the pylorus were rapidly collected and placed on a
cold ice plate (0°C). The dissection of brain parts was
carried out according to the atlas of Karten and Hodos
[33] and Henri M. Duvernoy [34]. The collected brain
tissue samples were first cleared of vessels and menin-
ges, while fecal matter and mesenteries were carefully
removed from intestinal samples, were weighed and
stored at - 80°C until analysis.Determination of neurotransmitters and their metabolites
Tissue samples were homogenized in cold 0.2% perchlo-
ric acid (PCA) at 5000 rpm with the help of Teflon glass
homogenizer (Wise stir HS 30 E). After centrifugation
(Centurion UK) at 12000 g/min (4°C) and filtered through
a 0.45 micron filter. Neurotransmitters and their metabo-
lites were analyzed using High Performance Liquid
Chromatography system (HPLC, Shimadzu, Japan) coupled
with Electrochemical Detection (ECD, ESA Coulochem III
model 5300), a pump (model LC-20AT), and an analytical
column (Teknokroma 3 × 150, 3um). Electrodes 1 and 2 of
the analytical cell were set at + 200 and – 200 mV respect-
ively, with a sensitivity of 2 mA, while the guard cell
(model 5020) potential was set at 500 mV. The mobile
phase consisted of 94 mM sodium dihydrogen orthophos-
phate, 40 mM Citric acid, 2.3 mM sodium 1-octane
sulphonic acid, 50 uM EDTA, and 10% acetonitrile (pH 3).
The flow rate was maintained at 0.6 mL/min. The limit of
detection was 11 pg for each of the neurotransmitter and
their metabolites except for HVA which was 19 pg. The
standards used were noradrenaline hydrochloride (NA), 3,
4-dihydroxyphenylacetic acid (DOPAC), dopamine hydro-
chloride (DA), 5-hydroxyindole-3-acetic acid (5HIAA),
Homovanillic acid (HVA) and serotonin (5HT) [35].
Statistical analysis
The differences between means were evaluated using a
one way analysis of variance (ANOVA) followed by
Dunnett or Tukey multiple comparison tests. P < 0.05
was considered as statistically significant. The animals
which showed complete suppression of R + V were not
included in statistical analysis for latency. Data repre-
sent the mean ± s.e.m. unless otherwise indicated.
Results
Effect of ZO-ActFr or MCP on cisplatin induced Retching
plus Vomiting (R + V)
Zingiber officinale acetone fraction (ZO-ActFr) at the
dose of 50 mg/kg provided maximum protection against
the R + V episodes which was ~ 58.13% (18 ± 4.2 epi-
sodes) (P < 0.05) as compared to cisplatin control. The
attenuation with the 25 & 100 mg doses observed was
44.18% (24 ± 4.1 episodes) and 27.9% (31 ± 5.6 episodes)
respectively, but the suppression was found to be statis-
tically non-significant (Table 1). The standard MCP
reduced the R + V episodes ~ 48.83% (22 ± 4.3 episodes)
(P < 0.05) and significantly increased (P < 0.01) the latency
time as compared to cisplatin control.
In this study the standard MCP and the treatments
failed to provide complete vomiting suppression, as all the
animals tested showed the vomiting response. ZO-ActFr
25 & 50 mg provided protection upto 16 hr and 12 hr,
respectively, while standard MCP was also found effective
upto 12 hr of observation period (Figure 2).
Table 1 Effect of ZO-ActFr or MCP on cisplatin induced R + V and jerking during a 24 h observation period










Saline + Cisplatin 02 ml/kg i.m. + 07 mg/kg i.v. 6/6 43 ± 4.3 68 ± 3.7 407 ± 64 16.6 ± 1.8
MCP + Cisplatin 30 mg/kg i.m. + 07 mg/kg i.v. 8/8 22 ± 4.3* 230 ± 84** 447 ± 103 11.5 ± 1.5
ZO-ActFr + Cisplatin 25 mg/kg i.m. + 07 mg/kg i.v. 7/7 24 ± 4.1 124 ± 21 246 ± 92 8.1 ± 1.0*
50 mg/kg i.m. + 07 mg/kg i.v. 7/7 18 ± 4.2* 77 ± 15 376 ± 97 11.3 ± 2.3
100 mg/kg i.m. + 07 mg/kg i.v. 8/8 31 ± 5.6 85 ± 15 569 ± 125 9.1 ± 1.6
*p < 0.05, **p < 0.01 (ANOVA followed by Tukey post hoc test).
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weight loss
Zingiber officinale acetone fraction (ZO-ActFr) did not
reduced jerking episodes at any dose treated and simi-
larly the standard MCP also failed to reduce the jerking
episodes as compared to cisplatin control. In cisplatin
control group animals lost upto 16% of their starting
body weight, while in treated groups only ZO-ActFr at the
dose of 25 mg attenuated the weight loss significantly
(P ˂ 0.05), while with other dose treatments the reduc-
tion observed was statistically non-significant (Table 1).
Effect of standard MCP or ZO-ActFr on basal level of
neurotransmitters and their metabolites in the brain areas
and small intestine
The standard MCP treatment reduced the concentration
of 5HIAA in the areas of AP and BS with significance of
(P < 0.05) and (P < 0.001), respectively as compared to
basal level. In addition, the decrease in the concentration
of HVA was also observed in the AP (P < 0.05) with
respect to basal HVA concentration (Table 2). ZO-ActFr
(50 mg/kg) did not altered the basal neurotransmitter
level except a decrease in the concentration of 5HIAA in
the brain area of BS, where the difference was found to
be statistically significant (P < 0.05) as compared to basal
level (Table 2).Figure 2 The effect of Zingiber officinale acetone fraction
(ZO-ActFr; 25, 50 & 100 mg/kg) and standard metoclopramide
(MCP; 30 mg/kg) on cisplatin induced Retching plus Vomiting
(R + V) during a 24 hr observation period. Each bar represents the
mean ± s.e.m of R + V episodes occurring during 4 hr periods (n = 6–8).Effect of standard MCP or ZO-ActFr on the level of
neurotransmitters and their metabolites in the brain areas
and small intestine at 3rd hour of cisplatin administration
Cisplatin treatment significantly increased (P < 0.001)
the concentration of 5-hydroxy tryptamine (5HT) in the
brain stem (BS) and intestine as compared to basal level,
while a non-significant increase was observed in the area
postrema (AP; Table 3). The treatment with standard
MCP (30 mg/kg) failed to change the concentration of
NA, DOPAC, DA, 5HIAA and HVA in all the brain
areas (AP & BS) and intestine in comparison to saline
control, but reduced the concentration of 5HT in the BS
and intestine significantly (P < 0.001) as compared to
cisplatin control (Table 3). In addition to its inhibitory
effects on 5HT, MCP also decreased 5HIAA concentra-
tion in both the brain areas (AP & BS) and intestine
significantly (P < 0.01-0.001, Table 3). ZO-ActFr (50 mg/kg)
reduced the level of 5HIAA (P < 0.001) and 5HT (P < 0.05 -
0.001) in the brain (AP & BS) and intestine as compared to
cisplatin control. No significant alteration was seen in NA,
DOPAC, DA and HVA in the brain (AP & BS) and
intestine (Table 3).
Effect of standard MCP or ZO-ActFr on the level of
neurotransmitters and their metabolites in the brain areas
and small intestine at 18th hour of cisplatin administration
Cisplatin increased the level of dopamine significantly
(P < 0.001) in the AP, while a non-significant trend
towards increase was observed in the areas of BS and in-
testine. 5HT concentrations were also raised in the brain
area of BS (P < 0.05) and intestine (P < 0.001), without
effecting the levels of NA, DOPAC, 5HIAA, HVA in the
areas of BS and intestine and 5HT in the AP (Table 4).
Treatment with standard metoclopramide (MCP; 30 mg/
kg) significantly decreased the upsurge of DA at the brain
area of AP (P < 0.001) and BS (P < 0.01). Furthermore a
decrease in the concentration of 5HIAA and 5HT was also
observed in the brain area of AP (P < 0.05 – 0.01) and
intestine (P < 0.001) as compared to cisplatin control
(Table 4). Pre-treatment with ZO-ActFr at (50 mg/kg)
reduced the contents of DA in the brain area of AP
(P < 0.001) and 5HT in the areas of BS and intestine
(P < 0.001) as compared to cisplatin control (Table 4).
Table 2 Effect of ZO-ActFr (50 mg/kg) administered 30 minutes before saline administration, on the basal level of
neurotransmitters and their metabolites (ng/mg tissue wet weight) in the brain areas and intestine in pigeons at
t = 3 hr (n = 6–8)
Treatment NA DOPAC DA 5HIAA HVA 5HT
Area postrema
Saline 0.610 ± 0.014 0.382 ± 0.111 0.590 ± 0.146 0.158 ± 0.036 0.913 ± 0.095 0.062 ± 0.034
MCP 30 mg 0.023 ± 0.005 0.017 ± 0.006 0.025 ± 0.012 0.005 ± 0.001* 0.121 ± 0.063* 0.023 ± 0.001
ZO-ActFr 50 mg 0.372 ± 0.036 0.122 ± 0.047 0.191 ± 0.037 0.039 ± 0.006 0.874 ± 0.204 0.045 ± 0.008
Brain stem
Saline 0.094 ± 0.022 0.060 ± 0.020 0.175 ± 0.078 0.060 ± 0.021 0.060 ± 0.016 0.010 ± 0.003
MCP 30 mg 0.119 ± 0.033 0.027 ± 0.006 0.044 ± 0.012 0.007 ± 0.001*** 0.066 ± 0.031 0.019 ± 0.002
ZO-ActFr 50 mg 0.056 ± 0.055 0.128 ± 0.127 0.082 ± 0.054 0.011 ± 0.001* 0.088 ± 0.021 0.020 ± 0.001
Intestine
Saline 0.194 ± 0.059 0.067 ± 0.020 0.090 ± 0.064 0.076 ± 0.058 0.056 ± 0.025 0.049 ± 0.016
MCP 30 mg 0.138 ± 0.039 0.054 ± 0.025 0.059 ± 0.018 0.097 ± 0.022 0.198 ± 0.102 0.062 ± 0.013
ZO-ActFr 50 mg 0.334 ± 0.131 0.037 ± 0.028 0.356 ± 0.113 0.050 ± 0.008 0.231 ± 0.110 0.103 ± 0.015
Standard MCP is also shown.
Values significantly different compared to basal level (saline) are indicated as *p < 0.05, ***p < 0.001 (ANOVA followed by Tukey post hoc analysis).
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In this study the extract of Zingiber officinale (ZO) was
screened against cisplatin induced Retching plus Vomiting
(R + V) in pigeons. Zingiber officinale (ZO; family
Zingiberaceae) commonly known as ginger; the plant
rhizome and is distributed and cultivated in Pakistan,
India, Malaysia, China, Taiwan and Bangladesh. The
standardization of ginger extract is reporting the quan-
tities of gingerols in concentration ~ 60 mg/g of extractTable 3 Effect of ZO-ActFr (50 mg/kg) or standard MCP (30 m
the level of neurotransmitters and their metabolites (ng/mg
pigeons at t = 3 hr of cisplatin administration (n = 6–8)
Treatment NA DOPAC DA
Area postrema
Saline 0.610 ± 0.014 0.382 ± 0.111 0.590 ± 0.1
Cisplatin 1.879 ± 1.622 0.312 ± 0.183 0.080 ± 0.0
MCP 30 mg 0.023 ± 0.005 0.017 ± 0.006 0.025 ± 0.0
ZO-ActFr 50 mg 0.605 ± 0.221 0.080 ± 0.027 1.147 ± 0.6
Brain stem
Saline 0.094 ± 0.022 0.060 ± 0.020 0.175 ± 0.0
Cisplatin 0.094 ± 0.024 0.173 ± 0.136 0.030 ± 0.0
MCP 30 mg 0.119 ± 0.033 0.027 ± 0.006 0.044 ± 0.0
ZO-ActFr 50 mg 0.633 ± 0.050 0.015 ± 0.002 0.133 ± 0.0
Intestine
Saline 0.194 ± 0.059 0.067 ± 0.020 0.090 ± 0.0
Cisplatin 0.222 ± 0.044 0.015 ± 0.003 0.022 ± 0.0
MCP 30 mg 0.138 ± 0.039 0.054 ± 0.025 0.059 ± 0.0
ZO-ActFr 50 mg 0.328 ± 0.036 0.088 ± 0.109 0.005 ± 0.0
Values significantly different compared to cisplatin control are indicated as *p < 0.0
are indicated as #p < 0.05, ###p < 0.001 (ANOVA followed by Tukey post hoc analysis[36]. In our study, we used acetone fraction of ZO
based on the study of Sharma and Co-workers [25],
where acetone fraction is reported to be more effective
to attenuate cisplatin induced emesis in dogs. Ginger have
been screened in postoperative nausea and vomiting in
clinics and is found to be superior to placebo and equally
effective as metoclopramide [29]. In this study, the dose of
50 mg was found to be highly effective in attenuating
cisplatin induced R +V, nonetheless longer but moderateg/kg) administered 30 mins before cisplatin challenge, on
tissue wet weight) in the brain areas and intestine in
5HIAA HVA 5HT
46 0.158 ± 0.036 0.913 ± 0.095 0.062 ± 0.034
30 0.316 ± 0.101# 0.555 ± 0.188 0.282 ± 0.120
12 0.005 ± 0.001* 0.121 ± 0.063* 0.023 ± 0.001
15 0.013 ± 0.001*** 0.171 ± 0.133 0.006 ± 0.002*
78 0.060 ± 0.021 0.060 ± 0.016 0.010 ± 0.003
01 0.036 ± 0.004### 0.028 ± 0.003 0.131 ± 0.020###
12 0.007 ± 0.001*** 0.066 ± 0.031 0.019 ± 0.002
77 0.018 ± 0.002*** 0.147 ± 0.054 0.037 ± 0.004***
64 0.076 ± 0.058 0.056 ± 0.025 0.049 ± 0.016
05 0.295 ± 0.024### 0.038 ± 0.004 0.665 ± 0.125###
18 0.097 ± 0.022 0.198 ± 0.102 0.062 ± 0.013
55 0.030 ± 0.013*** 0.124 ± 0.066 0.049 ± 0.021***
5, ***p < 0.001, while Values significantly different as compared to basal level
).
Table 4 Effect of ZO-ActFr (50 mg/kg) or standard MCP (30 mg/kg) administered 30 mins before cisplatin challenge, on
the level of neurotransmitters and their metabolites (ng/mg tissue wet weight) in the brain areas and intestine in
pigeons at t = 18 hr of cisplatin administration (n = 6–8)
Treatment NA DOPAC DA 5HIAA HVA 5HT
Area postrema
Saline 0.610 ± 0.014 0.382 ± 0.111 0.590 ± 0.146 0.158 ± 0.036 0.913 ± 0.095 0.062 ± 0.034
Cisplatin 0.268 ± 0.073 0.026 ± 0.010 7.366 ± 1.500### 0.188 ± 0.053 0.556 ± 0.114 0.181 ± 0.052##
MCP 30 mg 0.023 ± 0.005 0.017 ± 0.006 0.025 ± 0.012 0.005 ± 0.001* 0.121 ± 0.063* 0.023 ± 0.001
ZO-ActFr 50 mg 1.304 ± 1.014 0.229 ± 0.081 0.846 ± 0.407*** 0.082 ± 0.044 1.513 ± 0.817 0.127 ± 0.071
Brain stem
Saline 0.094 ± 0.022 0.060 ± 0.020 0.175 ± 0.078 0.060 ± 0.021 0.060 ± 0.016 0.010 ± 0.003
Cisplatin 0.067 ± 0.004 0.001 ± 0.000 0.175 ± 0.026 0.034 ± 0.003 0.009 ± 0.001 0.121 ± 0.010###
MCP 30 mg 0.119 ± 0.033 0.027 ± 0.006 0.044 ± 0.012 0.007 ± 0.001*** 0.066 ± 0.031 0.019 ± 0.002
ZO-ActFr 50 mg 0.014 ± 0.008 0.001 ± 0.000 0.080 ± 0.068 0.001 ± 0.000 0.009 ± 0.005 0.002 ± 0.000***
Intestine
Saline 0.194 ± 0.059 0.067 ± 0.020 0.090 ± 0.064 0.076 ± 0.058 0.056 ± 0.025 0.049 ± 0.016
Cisplatin 0.223 ± 0.036 0.005 ± 0.001 0.151 ± 0.042 0.329 ± 0.054 0.060 ± 0.007 0.463 ± 0.098###
MCP 30 mg 0.138 ± 0.039 0.054 ± 0.025 0.059 ± 0.018 0.097 ± 0.022 0.198 ± 0.102 0.062 ± 0.013
ZO-ActFr 50 mg 0.172 ± 0.064 0.001 ± 0.000 0.485 ± 0.218 0.009 ± 0.006 0.050 ± 0.030 0.017 ± 0.011***
Values significantly different compared to cisplatin control are indicated as *p < 0.05, ***p < 0.001, while Values significantly different compared to basal level are
indicated as ##p < 0.05, ###p < 0.001 (ANOVA followed by Tukey post hoc analysis).
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There are several lines of evidences explaining the anti-
emetic effect of ginger; in animal models ginger is shown
to enhance gastrointestinal transport i.e. having gastropro-
kinetic properties. Furthermore, ginger is having anti-
hydroxytryptamine activity in the isolated ileal segments
[37] as galanolactone, one of the component of ginger, has
been proved to be a competitive antagonist at ileal 5HT3
receptors. Thus anti-emetic effects could be brought about
by antagonism at 5HT3 receptors in the gastrointestinal
tract [37,38]. Furthermore, ginger has also been found to
be having inhibitory action on substance P and the expres-
sion of NK1 receptors [27]. Our results of current study
are indicative of promising anti-emetic activity of ginger
acetone extract against cisplatin induced vomiting in the
pigeon. Ginger acetone extract was selected to find out its
intrinsic antiemetic activity in line with its impact on
central and peripheral neurotransmitters (and metabolites)
involved in the act of vomiting, because the said fraction
was found to be more effective to attenuate cisplatin
induced vomiting in dogs as reported by Sharma and
co-workers [25].
Metoclopramide (MCP), which is a clinically relevant
anti-emetic with dopamine and 5-HT3 receptor antagon-
ist properties [39] was used as a positive control. The
dose of MCP that we selected is higher than required to
antagonize cisplatin induced emesis in other species
[40], and was based on a previous study in the pigeon
showing activity against reserpine-induced emesis [2].
The metoclopramide was selected as standard becauseof the intrinsic emetic activity of 5HT3 receptor antago-
nists in pigeon (unpublished data).
As evident from the literature, neurochemical mediators
of various types are responsible in vomiting circuits for
CIV, especially serotonin (5HT), dopamine, substance P
and prostaglandins are postulated to contribute in its
genesis [6,26,41,42]. The emetogenic anti-cancer agent
cisplatin induces biphasic vomiting both in human [43]
and in other vomiting species [27,44-46]. Neural ana-
lysis of cisplatin control group in pigeon model indi-
cated the upsurge of serotonin in the brain areas of BS
and intestine at acute time point (03 hr) suggesting the
neurotransmitter serotonin (5HT) as the triggering
mediator for acute phase response in pigeons. The
increase in 5HT concentration in our study is in line
with the previous findings in animal models where
5HT3 receptor antagonists (ondansetron, granisetron,
palonosetron etc.) are found to be effective against acute
phase of CIV [10]. Furthermore, at delayed time point
(18 hr) in pigeon the increase in the concentration of
dopamine at the level of AP and serotonin in the brain
area of BS and in the intestine is indicating the differential
involvement of neurotransmitters at this time point; as
CIV is thought to be a multifactorial phenomenon and
both the phases of vomiting are mechanistically different
[46], that’s why the prophylactic and intermittent adminis-
tration of single antiemetic agent fails to provide complete
control against cisplatin induced vomiting in clinics.
The pungent constituents collectively known as gin-
gerols have been reported to be having inhibitory effects
Ullah et al. BMC Complementary and Alternative Medicine  (2015) 15:34 Page 7 of 8on the upsurge of substance P both centrally and periph-
erally and NK1 receptors expression in the vomit model
of mink [27]. In our study, ZO-ActFr (50 mg) provided
maximum protection against cisplatin induced R + V in
pigeons, where the protection observed was ~ 58.13%.
ZO-ActFr (25 mg) also resulted in the decrease in jerks
(indicative of vomiting intensity) and reduced the weight
loss significantly. The reduction in jerks and weight loss
are the secondary parameters supporting the antiemetic
profile of ginger acetone extract. Furthermore, the im-
pact of ZO-ActFr on the major neurotransmitter media-
tors including dopamine and serotonin is encouraging
and is in support for its anti-emetic effect where
ZO-ActFr (50 mg) decreased the concentration of 5HT
and 5HIAA in the brain areas (AP & BS) and intestine
at acute time point (3 hr). Moreover, at delayed time
point (18 hr) resulted in the decreased concentration of
dopamine in the brain area of AP, while 5HT decrease
was observed at the level of BS and in the intestine.
Conclusions
In conclusion, ZO acetone fraction attenuated cisplatin
induced vomiting in the pigeon which is mediated
by both central and peripheral anti-serotonergic and
anti-dopaminergic components in a blended manner at
the two different time points. At the acute time point
(3rd hr), dominantly the anti-serotonergic effects were
seen centrally in the area postrema and brain stem as
well as peripherally at the level of intestine, while at the
delayed time point (18th hr) anti-serotonergic effects
were observed centrally in the brain stem and peripher-
ally in the intestine where centrally in the area postrema
there was anti-dopaminergic aftermath.
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